---
title: "majestec-1"
date: "2024-08-24"
tags:
  - building
---

> [!NOTE]
> ðŸŒ± created from: [[bispecific_antibodies_for_relapse_and_refractory_multiple_myeloma]]

# majestec-1

- Design: Phase 1-2 study, multi-center, open-label
- Number of patients: 165
- Patients characteristics: Relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure
- Agent: Teclistamab at a dose of 1.5 mg/kg body weight
- Treatment line: After at least three therapy lines, including triple-class exposure
- Trial Acronym or NCTId Number: NCT03145181 and NCT04557098

| Parameter                   | Result                                      |
| --------------------------- | ------------------------------------------- |
| Response Rate               | 63.0%                                       |
| Complete Response Rate      | 39.4%                                       |
| MRD-negativity Rate         | 26.7%                                       |
| Median Duration of Response | 18.4 months (95% CI, 14.9 to not estimable) |
| Median Duration of PFS      | 11.3 months (95% CI, 8.8 to 17.1)           |

- Highlight of [[toxicity_in_majestec-1.md|toxicity in majestec-1]]:
  - Common toxic effects included
    - cytokine release syndrome, neutropenia, anemia, thrombocytopenia, and infections.
    - Neurotoxic events occurred in a small percentage of patients.
- One line summary: Teclistamab showed promising efficacy in patients with triple-classâ€“exposed relapsed or refractory multiple myeloma, with manageable toxicities.

> Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. New England Journal of Medicine. 2022;387(6):495-505. doi:10.1056/nejmoa2203478

- further Reading: [[covid-19_and_majestec-1.md|COVID-19 and majestec-1]]
